| Literature DB >> 26340092 |
Lingling Cao1, Jian Ding1, Liguo Dong1, Jiayao Zhao1, Jiaming Su1, Lingyao Wang1, Yi Sui1, Tong Zhao1, Fei Wang1, Jingji Jin2, Yong Cai2.
Abstract
We previously identified an ATP-dependent human Ino80 (INO80) chromatin remodeling complex which shares a set of core subunits with yeast Ino80 complex. Although research evidence has suggested that INO80 complex functions in gene transcription and genome stability, the precise mechanism remains unclear. Herein, based on gene expression profiles from the INO80 complex-knockdown in HeLa cells, we first demonstrate that INO80 complex negatively regulates the p21Waf1/Cip1 (p21) expression in a p53-mediated mechanism. In chromatin immunoprecipitation (ChIP) and a sequential ChIP (Re-ChIP) assays, we determined that the INO80 complex and p53 can bind to the same promoter region of p21 gene (-2.2 kb and -1.0 kb upstream of the p21 promoter region), and p53 is required for the recruitment of the INO80 complex to the p21 promoter. RNAi knockdown strategies of INO80 not only led to prolonged progression of cell cycle phase G2/M to G1, but it also resulted in abnormal chromosome stability. Interestingly, high expression of p21 was observed in most morphologically-changed cells, suggesting that negative regulation of p21 by INO80 complex might be implicated in maintaining the cell cycle process and chromosome stability. Together, our findings will provide a theoretical basis to further elucidate the cellular mechanisms of the INO80 complex.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26340092 PMCID: PMC4560432 DOI: 10.1371/journal.pone.0137411
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
RT-qPCR primer sets used in paper.
| Primers | Directions | Sequences | Size (bp) |
|---|---|---|---|
| hIno80 | forward | 5'-CGGAATCGGCTTTTGCTA-3' | 292 |
| reverse | 5'-TGTCGGCTGGTCAGTTGG-3 | ||
| hArp8 | forward | 5'-CCAGGCTGAGAAGGGTGATA-3' | 200 |
| reverse | 5'-GCAGGAAGAGTGTCTGTGGC-3' | ||
| hIes6 | forward | 5'-ATGGCGGCGCAAATTCCAAT-3' | 247 |
| reverse | 5'-AATGGCAAAGGTTTGGCAGC-3' | ||
| hIes2 | forward | 5'-GGAGAAGCCCTGGAGTTGAG-3' | 199 |
| reverse | 5'-GGAACACTCTTGGTCCCCAG-3' | ||
| GAPDH | forward | 5'-ATCACTGCCACCCAGAAGAC-3' | 443 |
| reverse | 5'-ATGAGGTCCACCACCCTGTT-3' | ||
| p21 | forward | 5'-ATGTGGACCTGTCACTGTCTTG-3' | 140 |
| reverse | 5'-CGTTTGGAGTGGTAGAAATCTG-3' | ||
| BCCIP | forward | 5'-TCAAGAGTTGGTTCTACGCTTC-3' | 111 |
| reverse | 5'-CATGGGCAGAGCGATCTGT-3' | ||
| ATMIN | forward | 5'-CAACCAATCCCTAGACCAGACA-3' | 181 |
| reverse | 5'-GCATCACGGGTAGTTTAACCAAA-3' | ||
| CDK6 | forward | 5'-CCAGATGGCTCTAACCTCAGT-3' | 152 |
| reverse | 5'-AACTTCCACGAAAAAGAGGCTT-3' | ||
| CCNG1 | forward | 5'-GAGTCTGCACACGATAATGGC-3' | 168 |
| reverse | 5'-GTGCTTGGGCTGTACCTTCA-3' | ||
| CCNC | forward | 5'-CCTTGCATGGAGGATAGTGAATG-3' | 62 |
| reverse | 5'-AAGGAGGATACAGTAGGCAAAGA-3' | ||
| CCNH | forward | 5'-AGGCACTTGAACAGATACTGGA-3' | 132 |
| reverse | 5'-CCAATATGGGATAGCGGGTCT-3' | ||
| CDC34 | forward | 5'-GACGAGGGCGATCTATACAACT-3' | 113 |
| reverse | 5'-GAGTATGGGTAGTCGATGGGG-3' | ||
| p15 | forward | 5'-GGGAGGGTAATGAAGCTGAG-3' | 97 |
| reverse | 5'-GGCCGTAAACTTAACGACACT-3' | ||
| MAD2L1 | forward | 5'-TTCTCATTCGGCATCAAC-3' | 224 |
| reverse | 5'-TCCAGGACCTCACCACTT-3' | ||
| CDK2 | forward | 5’-CCAGGAGTTACTTCTATGCCTGA-3' | 90 |
| reverse | 5’-TTCATCCAGGGGAGGTACAAC-3' | ||
| p53 | forward | 5’-CAGCACATGACGGAGGTTGT-3' | 125 |
| reverse | 5’-TCATCCAAATACTCCACACGC-3' | ||
| P53-C | forward | 5’-ACTAAGCGAGCACTGCCCA-3' | 300 |
| reverse | 5’-TCAGTCTGAGTCAGGCCCTT-3' | ||
| P53-N | forward | 5’-ATGGAGGAGCCGCAGTCAG-3' | 264 |
| reverse | 5’-TGCTCCCTGGGGGCAGCTCG-3' | ||
| CyclinE1 | forward | 5’-ACTCAACGTGCAAGCCTCG-3' | 141 |
| reverse | 5’-GCTCAAGAAAGTGCTGATCCC-3' | ||
| Bax | forward | 5’-CTCAGGATGCGTCCACCAAGAA-3' | 287 |
| reverse | 5’-CTCCCGGAGGAAGTCCAATGTC-3' |
The enriched KEGG pathway of DEGs.
| Category | Term | Description | Count | P-value | Size |
|---|---|---|---|---|---|
| KEGG | hsa04115 | p53 signaling pathway | 21 | 5.89E-07 | 68 |
| KEGG | hsa05200 | Pathways in cancer | 47 | 5.57E-04 | 328 |
| KEGG | hsa05222 | Small cell lung cancer | 16 | 0.005016 | 84 |
| KEGG | hsa04520 | Adherens junction | 15 | 0.005605 | 77 |
| KEGG | hsa04110 | Cell cycle | 20 | 0.010399 | 125 |
| KEGG | hsa04510 | Focal adhesion | 28 | 0.013353 | 201 |
| KEGG | hsa04010 | MAPK signaling pathway | 34 | 0.021703 | 267 |
| KEGG | hsa05130 | Pathogenic Escherichia coli infection | 11 | 0.022704 | 57 |
| KEGG | hsa04120 | Ubiquitin mediated proteolysis | 20 | 0.025782 | 137 |
| KEGG | hsa04662 | B cell receptor signaling pathway | 13 | 0.026162 | 75 |
| KEGG | hsa04512 | ECM-receptor interaction | 14 | 0.027162 | 84 |
| KEGG | hsa05210 | Colorectal cancer | 14 | 0.027162 | 84 |
Notes: Count: the number of DEGs. Size: the total number of genes in the pathway
Abbreviations: DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Comparison between the Illumina fold-change and RT-qPCR fold-change.
| Gene | Gene | Gene | fold-change (siArp8) | fold-change (siIno80) | ||
|---|---|---|---|---|---|---|
| Symble | accession No. | description | Illumina | RT-qPCR | Illumina | RT-qPCR |
|
| NM_199246 | Cyclin G1 |
|
|
|
|
| CCNC | NM_001013399 | Cyclin C | 0.84 | -1.53 | 0.53 | -0.80 |
| CCNH | NM_001239 | Cyclin H | 1.12 | -2.17 | 0.42 | -0.06 |
|
| NM_001259 | Cyclin-dependent kinase 6 |
|
|
|
|
| CDC34 | NM_030771 | Coiled-coil domain containing 34 | 1.03 | 0.02 | 1.09 | -0.01 |
| CDKN2B | NM_078487 | Cyclin-dependent kinase inhibitor 2B | 0.62 | -0.06 | 0.63 | -1.38 |
| ATMIN | NM_015251 | ATM interactor | 1.56 | 1.43 | 3.41 | 0.43 |
| BCCIP | NM_016567 | BRCA2 and CDKN1A interacting protein | 0.83 | -2.81 | 0.45 | -1.37 |
|
| NM_001798 | Cyclin-dependent kinase 2 |
|
|
|
|
| CCNE1 | NM_001238 | Cyclin E1 | 1.05 | -1.03 | 1.38 | 0.54 |
| MAD2L1 | NM_002358 | MAD2 mitotic arrest deficient-like 1 | 0.81 | -1.23 | 0.43 | -1.32 |
|
| NM_078467 | Cyclin-dependent kinase inhibitor 1A |
|
|
|
|